Although limitations in radiotolerance of the immunocompromised mouse model used in our studies prevented in vivo studies of combined DMC1 depletion and IR, we found delayed tumor progression and increased survival with DMC1 depletion supports the therapeutic potential of DMC1 targeting. This evidence concerns the gene DMC1 and neoplasm.